Table 1 Patient characteristics

Prostate and urinary history in years prior to PrCa diagnostic biopsy

Age 55.8 symptoms of BPH and PSA 1.8, started on dutasteride. PSA dropped to 0.7 on dutasteride age 58.6, when dutasteride stopped. PSA then steadily rose from 2.8 at age 61, to 12 (percent free 13%) at age 63.6 despite the course of finasteride, just before PrCa diagnostic biopsy

Age 56.2 PSA 2.3 (26% free), Age 58.5 PSA 10 (19% free) led to prostate biopsy

Urinary symptoms just prior to PrCa diagnostic biopsy

Urinary urgency and nocturia

Urinary frequency and decreased urinary stream

Plasma PSA just prior to PrCa diagnostic biopsy

12 ng/mL

10 ng/mL

Family history of cancer in first-degree relatives

History of lethal cancer in father and mother

History of cancer in father

Race/ancestry

White/Finnish

White/Finnish

AJCC 7th edition clinical stage ( in use at study entry)

T2b NxM0

T2c NxM0

Biopsy Gleason Grade Group

5

5

Pathologic stage (after RP)

pT3aN1M0, stage group IVA

pT3bN1M0, stage group IVA

Radical prostatectomy Gleason Grade Group

5

5

Age at PrCa Diagnostic Biopsy/RP

63.6/63.8 years

58.5/58.7 years

Postoperative status (patient follow-up period: up to 6 years after RP)

Received EBRT to prostate fossa in the postoperative period. Put on leuprolide and bicalutamide. PSA nadir post RP 0.3 ng/mL. PSA 6 years postop 0.11 ng/mL. Status M0 at 6 years postop

Received EBRT to prostate fossa and pelvic lymph nodes in the postoperative period. Bone metastasis found 2 years post RP. PSA nadir post-RP 0.9 ng/mL, > 1000 ng/mL at 6 years postop after bicalutamide, orchiectomy, cabazitaxel, carboplatin, and radium 223 treatments, shifted to palliative care with status M1c